Back to top
more

Dare Bioscience (DARE)

(Delayed Data from NSDQ)

$0.29 USD

0.29
380,661

-0.01 (-3.80%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.29 0.00 (1.40%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis

Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of -63.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy

Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.

New Strong Sell Stocks for December 30th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for December 15th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for December 1st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.